(GMAB) Genmab A/S Business Model Canvas Research

Genmab A/S works with CureVac on differentiated mRNA-based antibody products in research and early development, extending Genmab A/S beyond standard antibody discovery. No deal value or revenue split has been publicly disclosed, so the strategic value is the technology fit, not near-term sales.

• Research-stage mRNA antibody work
• Broadens Genmab A/S technology base
• No public financial terms disclosed

Genmab's key partnerships with BioNTech, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics keep 4 active alliance tracks running across oncology and other disease areas. That setup broadens the pipeline and shares R&D risk, so Genmab can back multiple programs without funding each one alone.

• 4 active alliances
• Oncology plus broader diseases
• Risk shared across programs

Genmab’s commercial launch support keeps revenue flowing from 5 marketed products: DARZALEX, teprotumumab, ofatumumab, amivantamab, and tisotumab vedotin. It covers supply, medical support, and lifecycle management, so R&D output moves into paid sales and royalties; DARZALEX remains the key cash engine, with 2025/2026 rollout work focused on expanding approved uses and access.

• 5 marketed products
• Supply and medical support
• Lifecycle management
• R&D to revenue bridge

Alliance management is central to Genmab A/S because its model depends on partner-led development with Seagen, AbbVie, CureVac, BioNTech, Janssen, Novo Nordisk, BliNK, and Bolt. Genmab keeps milestone payments, joint governance, and shared development plans aligned, which protects economics and keeps partnered programs moving.

• Runs multi-partner governance.
• Negotiates milestones and royalties.
• Aligns shared R&D plans.
• Supports a partnered revenue model.

Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark. The Copenhagen HQ is the company’s operating base, anchoring research, development, and corporate management for its antibody portfolio.

In 2025, Genmab reported DKK 2025 figures in its annual report, reinforcing how central the Copenhagen site is to execution and oversight across the business.

• Founded in 1999
• Headquartered in Copenhagen
• Hosts R&D and management
• Main operating base

Genmab A/S depends on patents, licenses, and co-development deals to shield its antibody platform and keep access to key markets. These rights also drive royalties and milestone income, with the strongest proof point being the DARZALEX franchise, which generated more than $9 billion in global sales in 2024 and still feeds Genmab’s economics through partner contracts.

• Patents protect platform science
• Licenses secure commercial access
• Co-dev deals support milestone income
• Royalties track partner sales

Genmab A/S has 7 Phase 2 programs and about 20 preclinical programs, so its pipeline is spread across near-term and longer-term shots. That depth lowers dependence on any single asset and supports multiple paths to future revenue.

• 7 Phase 2 assets
• About 20 preclinical programs
• Near-term and long-term depth
• Less single-product risk

Genmab A/S uses a shared risk partner model: partners help fund, run, and scale development, so Genmab can widen access while lowering execution risk. In 2025, this model supported collaboration-driven revenue and royalties that reached multi-billion DKK levels, while also spreading cost and launch risk across partners.

• Partners fund development costs
• Genmab reduces execution risk
• Broader market access

Genmab A/S needs hard clinical and health-economic proof to win reimbursement: payer access follows trial outcomes, not promotion. In FY2025, its scale and evidence base matter because every payer decision hinges on value shown in outcomes data and budget impact.

• Access depends on data quality.
• Health-economic proof drives reimbursement.
• Trial wins shape payer trust.

For payers, the relationship is simple: better efficacy and safety data mean faster coverage, while weak value evidence slows uptake. Genmab A/S’s 2025 commercialization strategy is built around demonstrating measurable patient benefit and cost value to support access.

Genmab A/S keeps customer ties alive after launch by adding new clinical data, filing label expansions, and coordinating supply for products like DARZALEX and EPKINLY. This lifecycle management helps extend product life, support payer access, and protect revenue as new indications are approved.

• New data drives label expansion.
• Supply coordination protects launch demand.
• Post-launch support extends product life.

Genmab A/S uses congresses and journals to publish 2025–2026 clinical readouts, especially for its antibody and bispecific pipeline, so specialists can judge efficacy and safety from peer-reviewed data. These channels support credibility and keep pipeline assets visible while the company scales beyond its marketed portfolio.

• Peer-reviewed data builds specialist trust
• Congress abstracts lift pipeline visibility
• 2025–2026 readouts drive investor attention

Genmab A/S uses medical science liaisons and digital channels to explain product data, safety, and real-world use, while keeping a live two-way exchange with clinicians. This model supports faster access to evidence and helps field teams answer questions from a global oncology base.

• Medical science liaisons share trial data.
• Digital tools extend product education.
• Two-way dialogue supports adoption.

Hospitals and physicians are Genmab A/S’s core economic customers: oncologists, hematologists, endocrinologists, and neurologists prescribe, administer, and monitor therapies in high-cost settings. In 2025, Genmab’s partnered and owned medicines were used in care pathways across major cancer and specialty-disease centers, where treatment choice and reimbursement decisions are made.

• Key buyers: hospitals and specialists
• Role: prescribe, administer, monitor
• Focus: oncology and specialty care

Genmab’s biopharma customers are partners like Seagen, AbbVie, CureVac, BioNTech, Janssen, Novo Nordisk, BliNK, and Bolt; they buy licenses, antibody tech, and co-development access. This segment is non-patient demand: in 2025, partner-led deals and royalties still drove a large share of Genmab’s top line, including Darzalex-linked economics.

• Licenses and collaboration access
• Eight named partner companies
• Royalties plus milestone-driven demand

Genmab A/S SG&A stays high because each launch, medical affairs team, and global support function adds fixed overhead; the burden grows as more products and countries are added, plus partner support lifts admin cost. In the latest reporting cycle, this line remained one of the key operating expenses tied to the company’s expanding commercial footprint.

• Launches add sales staff and marketing spend
• Medical affairs lifts field and support costs
• More markets mean higher admin overhead
• Partner programs add coordination costs

Genmab A/S relies on partnered assets, so royalty fees, profit splits, and milestone payments are built into collaboration contracts. That means commercial wins can lift revenue fast, but they also trim net margins because partners keep a share of the upside.

• Royalties rise with partner sales.
• Milestones hit on trial and launch events.
• Profit sharing cuts full margin capture.

Profit share income is a core Genmab A/S revenue stream: select alliances give Genmab a share of economics when partnered products succeed. Johnson & Johnson reported Darzalex sales of US$11.7 billion in 2025, showing how one hit asset can create large upside for Genmab without full commercial risk.

• Shared economics on successful alliances
• Upside rises with partner sales
• Core, high-margin model feature

Genmab can book supply and collaboration revenue from development support, tech transfer, and manufacturing tied to its antibody platform and GMP capacity. In 2025, this stream stayed smaller than royalties and product sales, but it helped diversify income across Genmab's 4 approved medicines and multiple partner deals.

• Paid for development support
• Uses scientific and manufacturing assets
• Complements royalties and product sales